Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805)
Phase II Clinical Trial of Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
Sponsor: Eli Lilly and Company
Terminated
Abemaciclib efficacy
Other terminated trials from Eli Lilly and Company
A PHASE2 clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Eli Lilly and Company and has accumulated 12 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Apr 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Apr 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .